Vaccinex sees long term value in building clinical programs that beneficially impact patient care. With that goal in mind, we are building a pipeline of novel candidate therapeutics that we hope will improve upon existing therapies and offer patient treatment options that improve their quality of life. Use the menu on the left to browse our clinical programs.

 

Product Pipeline

Click to enlarge

 

Active Clinical Trials

Neurology

A Phase 2, multi-center, randomized, double-blinded, placebo-controlled clinical trial in subjects with late prodromal and early manifest Huntington disease (HD) to assess safety, tolerability, pharmacokinetics, and efficacy of VX15/2503
Link to clinicaltrials.gov page for this study

 

Immuno-oncology

VX15/2503 in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer
Phase 1b/2 Study of VX15/2503 in combination with avelumab in non-small cell lung cancer
Link to clinicaltrials.gov page for this study
Link to press release

 

Additional immuno-oncology clinical trials involving pepinemab (VX15/2503):

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients with Stage III or IV Melanoma
Phase I Study of Combining an Anti-SEMA4D Antibody VX15/2503 with Checkpoint Inhibitors for Patients with Advanced Melanoma Who Have Progressed on Prior Anti-PD1/L1 Based Therapies

Sponsor:
Jonsson Comprehensive Cancer Center (UCLA)

Collaborator:
National Cancer Institute (NCI)

This randomized pilot phase I trial studies the side effects and best dose of anti-SEMA4D monoclonal antibody VX15/2503 when given together with nivolumab or ipilimumab in treating patients with stage III or IV melanoma. Monoclonal antibodies, such as anti-SEMA4D monoclonal antibody VX15/2503, nivolumab, and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

Link to clinicaltrials.gov page for this study

 

VX15/2503 in Treating Younger Patients with Recurrent, Relapsed, or Refractory Solid Tumors
A Phase 1/2 Trial of VX15/2503, a Humanized Monoclonal Antibody to Semaphorin 4D, in Pediatric patients with Relapsed or Refractory Solid Tumors

Sponsor:
Children’s Oncology Group

Collaborator:
National Cancer Institute (NCI)

This phase I/II trial studies the side effects and best dose of anti-SEMA4D monoclonal antibody VX15/2503 (VX15/2503) and to see how well it works in treating younger patients with solid tumors that have come back after prior treatment, or did not respond to prior treatment. Monoclonal antibodies, such as VX15/2503, may interfere with the ability of tumor cells to grow and spread.

Link to clinicaltrials.gov page for this study
Link to press release

 

VX15/2503 and Immunotherapy in Resectable Solid Tumors
  1. Phase I Integrated Biomarker Trial of VX15/2503 in Combination with Ipilimumab or Nivolumab as Neoadjuvant Treatment in Patients with Pancreatic and Colorectal Cancer. Link to clinicaltrials.gov page for this study.
  2. Phase I Integrated Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer. Link to clinicaltrials.gov page for this study.
  3. Phase I Integrated Biomarker Trial of VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma. Link to clinicaltrials.gov page for this study.

Sponsor:
Emory University

Collaborator:
Vaccinex Inc.

These randomized phase I trials are intended to study how anti-SEMA4D monoclonal antibody VX15/2503 (pepinemab) in combination with or without ipilimumab or nivolumab may affect the tumor micro-environment in patients with various solid tumor cancers. Monoclonal antibodies, such as anti-SEMA4D monoclonal antibody VX15/2503, ipilimumab, and nivolumab, may interfere with the ability of tumor cells to grow and spread.

 

Company Policy on Expanded Access and Compassionate Use